Latest Strategy News

Atomos has finalized its acquisition of Flanders Scientific for $2.35 million cash plus shares, funded by a new $10 million finance facility from Commonwealth Bank. The deal broadens Atomos’ professional video monitoring reach and is expected to add $1 million EBITDA before growth.

Cauldron Energy has won two co-funded grants totaling up to AUD 217,750 from the WA Government’s Exploration Incentive Scheme to advance uranium exploration at its Yanrey Project, targeting key palaeochannels including the high-priority Curtis channel.

Viking Mines has advanced its Linka Tungsten Project by completing a conceptual process flowsheet that incorporates recent metallurgical results and enables future processing upgrades. Preliminary engineering and cost evaluations are underway ahead of planned drilling in the June quarter.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Nido Education has expanded its footprint with a $9.1 million acquisition of four child care services, adding 348 places and an estimated $1.9 million annualised EBITDA. The company is also actively pursuing further acquisitions beyond its incubation pipeline amid sector demand challenges.

SenSen Networks reported a 17% increase in annual recurring revenue to $11 million and positive operating cash flow of $0.9 million in Q3 FY26 despite supply chain disruptions delaying some projects. The company’s full-year EBITDA is expected to improve significantly over FY25.

Corella Resources has agreed to acquire a majority interest in the Chobe Project, expanding its footprint in Western Australia’s emerging rare earths and niobium hotspot. The acquisition is backed by a heavily oversubscribed $5 million capital raise.

Forrestania Resources has reported a series of high-grade gold intercepts from drilling at British Hill, Mt Palmer, and Johnson Range projects in Western Australia, underscoring its methodical exploration approach and potential resource growth.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.

Tivan Limited has added Major Michael Stone (Retd) to its Technical Advisory Group, leveraging his 25 years of Timor-Leste expertise to boost local engagement and strategic guidance for its copper-gold projects. This move bolsters Tivan’s in-country capabilities as it advances its Turiscai, Baucau, and Ossu exploration portfolio.

Brazilian Rare Earths (ASX: BRE) has reported substantial expansion of its Monte Alto rare earth project with ultra high-grade drilling results and validated low-temperature processing delivering 97% recovery. The company also secured a Trial Mining Licence enabling early production and bulk shipments.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.